Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking

Oncogene

Volumn 30, Issue 48, 2011, Pages 4780-4790

  Kim, D S ^a   Choi, Y B ^a   Han, B G ^a   Park, S Y ^a   Jeon, Y ^a   Kim, D H ^a   Ahn, E R ^a   Shin, J E ^a   Lee, B I ^a   Lee, H ^a   Hong, K M ^a   Kim, S Y ^a,b  

^a National Cancer Center   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

EPO; HIF 1 ; IGF 1R; NF B; Transglutaminase 2; Von Hippel Lindau

Indexed keywords

ENZYME; ENZYME TGASE 2; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CELL SURVIVAL; CONTROLLED STUDY; DEPLETION; DOWN REGULATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; KIDNEY CANCER; KIDNEY PARENCHYMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; PROTEIN POLYMERIZATION; PROTEIN STABILITY;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; GENES, TUMOR SUPPRESSOR; GTP-BINDING PROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NEOPLASMS; NF-KAPPA B; TRANSGLUTAMINASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

MUS MUSCULUS;

EID: 82455188065     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.183     Document Type: Article

References (28)

1. Carroll VA, Ashcroft M. (2006). Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 66: 6264-6270.
2. Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X. (2008). The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci 13: 3273-3287. (Pubitemid 351594682)
3. Cowey CL, Rathmell WK. (2009). VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep 11: 94-101.
4. Curtis CD, Goggins M. (2005). DNA methylation analysis in human cancer. Methods Mol Med 103: 123-136.
5. Gangadharan C, Thoh M, Manna SK. (2009). Inhibition of constitutive activity of nuclear transcription factor kappaB sensitizes doxorubicin-resistant cells to apoptosis. J Cell Biochem 107: 203-213.
6. Herman JF, Mangala LS, Mehta K. (2006). Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 25: 3049-3058. (Pubitemid 43780469)
7. Iismaa SE, Mearns BM, Lorand L, Graham RM. (2009). Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol Rev 89: 991-1023.
8. Jang GY, Jeon JH, Cho SY, Shin DM, Kim CW, Jeong EM et al. (2010). Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells. Oncogene 29: 356-367.
9. Jung Y, Isaacs JS, Lee S, Trepel J, Liu ZG, Neckers L. (2003). Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation. Biochem J 370: 1011-1017. (Pubitemid 36399095)
10. Kaelin Jr WG. (2002). Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2: 673-682. (Pubitemid 37328918)
11. Kim DS, Han BG, Park KS, Lee BI, Kim SY, Bae CD. (2010). I-kappaBalpha depletion by transglutaminase 2 and mu-calpain occurs in parallel with the ubiquitin-proteasome pathway. Biochem Biophys Res Commun 399: 300-306.
12. Kim DS, Park KS, Kim SY. (2009). Silencing of TGase 2 sensitizes breast cancer cells to apoptosis by regulation of survival factors. Front Biosci 14: 2514-2521.
13. Kim DS, Park SS, Nam BH, Kim IH, Kim SY. (2006). Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res 66: 10936-10943.
14. Kim JM, Voll RE, Ko C, Kim DS, Park KS, Kim SY. (2008). A new regulatory mechanism of NF-kappaB activation by I-kappaBbeta in cancer cells. J Mol Biol 384: 756-765.
15. Lee J, Kim YS, Choi DH, Bang MS, Han TR, Joh TH et al. (2004). Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. J Biol Chem 279: 53725-53735. (Pubitemid 40051881)
16. Maiuri L, Luciani A, Giardino I, Raia V, Villella VR, D'Apolito M et al. (2008). Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation. J Immunol 180: 7697-7705.
17. Mehta K, Fok J, Miller FR, Koul D, Sahin AA. (2004). Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 10: 8068-8076. (Pubitemid 39587548)
18. Otrock ZK, Hatoum HA, Awada AH, Ishak RS, Shamseddine AI. (2009). Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives. Crit Rev Oncol Hematol 70: 93-102.
19. Park KS, Kim DS, Jeong KC, Kim SY. (2009). Increase in transglutaminase 2 expression is associated with NF-kappaB activation in breast cancer tissues. Front Biosci 14: 1945-1951.
20. Park SS, Kim JM, Kim DS, Kim IH, Kim SY. (2006). Transglutaminase 2 mediates polymer formation of I-kappaBalpha through Cterminal glutamine cluster. J Biol Chem 281: 34965-34972.
21. Qi H, Ohh M. (2003). The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factorinduced cytotoxicity by suppressing the nuclear factor-kappaBdependent antiapoptotic pathway. Cancer Res 63: 7076-7080. (Pubitemid 37413442)
22. Seo JS, Jung EY, Kim JH, Lyu YS, Han PL, Kang HW. (2010). A modified preparation (LMK03) of the oriental medicine Jangwonhwan reduces Abeta(1-42) level in the brain of Tg-APPswe/PS1dE9 mouse model of Alzheimer disease. J Ethnopharmacol 130: 578-585.
23. Shao M, Cao L, Shen C, Satpathy M, Chelladurai B, Bigsby RM et al. (2009). Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res 69: 9192-9201.
24. Tischoff I, Tannapfel A. (2008). Epigenetic alterations in colorectal carcinomas and precancerous lesions. Z Gastroenterol 46: 1202-1206.
25. Verma A, Mehta K. (2007). Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Updat 10: 144-151. (Pubitemid 47446401)
26. Wang GL, Semenza GL. (1993). General involvement of hypoxiainducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 90: 4304-4308. (Pubitemid 23134215)
27. Yuen JS, Akkaya E, Wang Y, Takiguchi M, Peak S, Sullivan M et al. (2009). Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer. Mol Cancer Ther 8: 1448-1459.
28. Yuen JS, Cockman ME, Sullivan M, Protheroe A, Turner GD, Roberts IS et al. (2007). The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene 26: 6499-6508. (Pubitemid 47530598)